Inotuzumab – Uses, Dosage, Side Effects, Interaction Inotuzumab ozogamicin is an antibody-drug conjugate used to treat B-cell precursor acute lymphoblastic leukemia (ALL). Inotuzumab ozogamicin is an antibody-drug conjugate using linker and cytotoxic drug technology similar to that developed for the ground-breaking treatment Mylotarg (Gemtuzumab ozogamicin), which was approved by the US FDA in 2000 for the treatment of acute myeloid leukemia. Inotuzumab ozogamicin consists of a recombinant humanized IgG4 kappa CD22-targeting monoclonal antibody covalently attached to calicheamicin derivative, N-acetyl-gamma-calicheamicin dimethyl hydrazide, which is a potent DNA-binding cytotoxic agent [rx]. Developed by Pfizer and UCB, inotuzumab ozogamicin was granted approval by the EU in June 2017 followed by FDA on August 17th, 2017 for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). ALL is a rapidly progressing cancer of the bone marrow that is associated with high mortality rates and low therapeutic response from standard chemotherapies in relapsing conditions. In a randomized trial, inotuzumab ozogamicin displayed higher percentages of patients undergoing long periods of complete remission with no evidence of disease in comparison to patients receiving alternative chemotherapy [rx]. Mechanism of action Inotuzumab ozogamicin is comprised of cytotoxic antibiotic N-acetyl-gamma-calicheamicin dimethyl hydrazide attached to a humanized monoclonal IgG4 antibody via 4-(4 acetylphenoxy) butanoic acid (acetyl butyrate) linker. The drug exerts a potent cytotoxic effect against CD22+ B-cell lymphoma when the antibody binds to the CD22 receptor on the surface of B cells. The drug-CD22 complex is rapidly internalized into the cell, forming an endosome that subsequently fuses with lysosomes. N-acetyl-gamma-calicheamicin dimethyl hydrazide is then intracellularly released into the acidic environment. N-acetyl-gamma-calicheamicin dimethyl hydrazide is a calicheamicin derivative, which is naturally produced by the bacterium Micromonospora Tinospora, and is toxic to the body when not bound to the antibody. It mediates apoptosis of the cell by binding to the minor groove of DNA in a sequence-specific manner and undergoing a structural change to generate diradicals [rx]. These changes abstract hydrogen ions from the phosphodiester bonds of double-stranded DNA, resulting in breaks and cell apoptosis [rx]. Indications Indicated as monotherapy for the treatment of adults with relapsed or refractory CD22-positive B cell precursor acute lymphoblastic leukemia (ALL). Refractory B-cell precursor acute lymphoblastic leukemia Relapsed B cell precursor Acute lymphoblastic leukemia Inotuzumab ozogamicin is used to treat relapsed or refractory B-cell precursor acute lymphoblastic leukemia. Use in Cancer Inotuzumab ozogamicin is approved to treat: B-cell acute lymphoblastic leukemia (ALL). It is used in adults whose cancer has relapsed or is refractory (does not respond to treatment). Inotuzumab ozogamicin is also being studied in the treatment of other types of cancer. Contraindications a bad infection acute leukemia low amount of magnesium in the blood low amount of calcium in the blood low amount of sodium in the blood low amount of potassium in the blood hemolytic uremic syndrome, a condition that affects the kidney and the blood anemia decreased blood platelets low levels of white blood cells a painful condition that affects the nerves in the legs and arms called peripheral neuropathy sudden blindness and pain upon moving the eye ototoxicity, damage to the inner ear that affects hearing or balance hearing loss a heart attack a clot in the lung a stroke inflammation of blood vessels in the brain or spinal cord Raynaud’s phenomenon, a condition where blood vessels constrict too much with coldness or stress blood clot in a deep vein of the extremities thrombotic thrombocytopenic purpura, a type of blood disorder decreased kidney function vomiting amount of uric acid in the blood pregnancy a patient who is producing milk and breastfeeding TPMT poor metabolizer a type of brain disorder called posterior reversible encephalopathy syndrome a clot in the aorta kidney disease with likely reduction in kidney function Dosage Strengths: 0.9 mg Acute Lymphoblastic Leukemia Cycle 1 (total dose is 1.8 mg/m2/cycle): Day 1: 0.8 mg/m2 IV Day 8: 0.5 mg/m2 IV Day 15: 0.5 mg/m2 IV Duration of therapy: Cycle 1 is 21 days in duration, but may be extended to 28 days (7-day therapy-free interval starting on Day 21) if the patient achieves a complete remission (CR) or complete remission with incomplete hematologic recovery (CRi), and/or to allow for recovery from toxicity Subsequent Cycles: For patients who achieve a CR or CRi (total dose is 1.5 mg/m2/cycle): Day 1: 0.5 mg/m2 IV Day 8: 0.5 mg/m2 IV Day 15: 0.5 mg/m2 IV Duration of therapy: 28 days (7-day therapy free interval starting on Day 21) OR For patients who do not achieve a CR or CRi (total dose is 1.8 mg/m2/cycle): Day 1: 0.8 mg/m2 IV Day 8: 0.5 mg/m2 IV Day 15: 0.5 mg/m2 IV Duration of therapy: 28 days (7-day therapy free interval starting on Day 21); patients who do not achieve a CR or CRi within 3 cycles should discontinue therapy For patients proceeding to hematopoietic stem cell transplant (HSCT): Duration of therapy: 2 cycles; a third cycle may be considered for those patients who do not achieve CR or CRi and minimal residual disease (MRD) negativity after 2 cycles For patients not proceeding to HSCT: Duration of therapy: Additional cycles of treatment, up to a maximum of 6 cycles, may be administered. Premedicate patients with a corticosteroid, an antipyretic, and an antihistamine prior to dosing. Infuse for 1 hour at a rate of 50 mL/hr. Doses on days 8 and 15 may be varied by plus or minus 2 days (maintain a minimum of 6 days between doses). Complete remission (CR) is defined as less than 5% blasts in bone marrow and the absence of peripheral blood leukemic blasts, full recovery of peripheral blood counts [platelets 100 x 10(9)/L or greater and absolute neutrophil count (ANC) 1 x 10(9)/L or greater] and resolution of any extramedullary disease. Complete remission with incomplete hematologic recovery (CRi) is defined as less than 5% blasts in bone marrow and the absence of peripheral blood leukemic blasts, full recovery of peripheral blood counts [platelets less than 100 x 10(9)/L and ANC less than 1 x 10(9)/L] and resolution of any extramedullary disease. For patients with circulating lymphoblasts, cytoreduction with a combination of hydroxyurea, steroids, and/or vincristine to a peripheral blast count of 10,000/mm3 or less is recommended prior to the first dose. Observe patients for infusion reactions during and for at least 1 hour after the end of the infusion. Renal Dose Adjustments Mild (CrCl 60 to 89 mL/min), moderate (CrCl 30 to 59 mL/min), or severe (CrCl 15 to 29 mL/min) renal impairment: No adjustment recommended. End-stage renal disease (CrCl less than 15 mL/min): Data not available Dose Adjustments Dose Adjustments for Hematologic Toxicities: If ANC is 1 x 10(9)/L or greater prior to starting of therapy: If ANC decreases, interrupt the next cycle of therapy until recovery of ANC to 1 x 10(9)/L or greater. Discontinue therapy if low ANC persists for greater than 28 days and is probably related to this drug. If the platelet count is 50 x 10(9)/L or greater prior to starting therapy If the platelet count decreases, interrupt the next cycle of therapy until the platelet count recovers to 50 x 10(9)/L or greater. Discontinue therapy if low platelet count persists for greater than 28 days and is probably related to this drug. If ANC is less than 1 x 10(9)/L and/or platelet count is less than 50 x 10(9)/L prior to start of therapy: If ANC or platelet count decreases interrupt the next cycle of therapy until at least one of the following occurs: 1) ANC and platelet counts recover to at least baseline levels for the prior cycle OR 2) ANC recovers to 1 x 10(9)/L or greater and platelet count recovers to 50 x 10(9)/L or greater OR 3) Stable or improved disease (based on most recent bone marrow assessment) and the ANC and platelet count decrease is due to the underlying disease (not considered to have been caused by this drug). Dose Adjustments for Nonhematologic Toxicities: Veno-occlusive disease (VOD) or other severe liver toxicity: Permanently discontinue therapy. Total bilirubin greater than 1.5 x upper limit of normal (ULN) and AST/ALT greater than 2.5 x ULN: Interrupt therapy until recovery of total bilirubin to 1.5 x ULN or less and AST/ALT to 2.5 x ULN or less prior to each dose unless due to Gilbert’s syndrome or hemolysis; permanently discontinue therapy if total bilirubin does not recover to 1.5 x ULN or less or AST/ALT does not recover to 2.5 x ULN or less. Infusion-related reaction: Interrupt the infusion and manage medically; depending on the severity of the reaction, consider discontinuation of therapy and administration of steroids and antihistamines; for severe or life-threatening infusion reactions, permanently discontinue therapy. Nonhematologic toxicity Grade 2 or greater: Interrupt therapy until recovery to Grade 1 or pretreatment Grade levels prior to each dose. Dose Adjustments Depending on Duration of Dosing Interruption Due to Nonhematologic Toxicity: Interruption of less than 7 days (within a cycle): Interrupt the next dose (maintain a minimum of 6 days between doses). Interruption of 7 days or more: Omit the next dose in the cycle. Interruption of 14 days or more: After recovery, decrease the dose by 25% for the next cycle; if further dose modification is required, reduce the number of doses to 2 per cycle for subsequent cycles; if a 25% decrease in the total dose followed by a decrease to 2 doses per cycle is not tolerated, then permanently discontinue therapy. Interruption of more than 28 days: Consider permanent discontinuation of therapy. Side Effects The Most Common dizziness lightheadedness fever, chills, cough, or other signs of infection unusual bleeding or bruising black and tarry stools red blood in stools pale skin fatigue More common fever, weakness, cold, or flu symptoms; cough, trouble breathing; swollen gums, mouth sores; pale skin, easy bruising, skin sores; a headache with chest pain and severe dizziness, fainting, fast or pounding heartbeats; signs of liver problems–upper stomach pain, jaundice (yellowing of the skin or eyes), or rapid weight gain, swelling in your arms or legs, painful swelling in your midsection; or unusual bleeding gums, abnormal vaginal bleeding, blood in your urine or stools, coughing up blood or vomit that looks like coffee grounds. Rare Black, tarry stools bleeding gums blood in the urine or stools chest pain chills cough or hoarseness coughing up blood difficulty in breathing or swallowing dizziness fever headache increased menstrual flow or vaginal bleeding lower back or side pain nosebleeds painful or difficult urination pale skin paralysis pinpoint red spots on the skin prolonged bleeding from cuts red or dark brown urine sore throat sores, ulcers, or white spots on the lips or in the mouth swollen glands troubled breathing with exertion unusual bleeding or bruising unusual tiredness or weakness yellow eyes or skin Drug Interaction DRUG INTERACTION Abciximab The risk or severity of adverse effects can be increased when Abciximab is combined with Inotuzumab ozogamicin. Abemaciclib The serum concentration of Abemaciclib can be increased when it is combined with Inotuzumab ozogamicin. Abrocitinib The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Abrocitinib. Adalimumab The risk or severity of adverse effects can be increased when Adalimumab is combined with Inotuzumab ozogamicin. Aducanumab The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Aducanumab. Afatinib The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Afatinib. Alemtuzumab The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Inotuzumab ozogamicin. Alirocumab The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Alirocumab. Ambrisentan The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Ambrisentan. Amiodarone The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Amiodarone. Amivantamab The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Amivantamab. Anifrolumab The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Anifrolumab. Ansuvimab The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Ansuvimab. Anthrax immune The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Anthrax immune globulin human. Antilymphocyte The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Antilymphocyte immunoglobulin (horse). Antithymocyte The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Inotuzumab ozogamicin. Apalutamide The serum concentration of Inotuzumab ozogamicin can be decreased when it is combined with Apalutamide. Apixaban The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Apixaban. Arsenic trioxide The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Arsenic trioxide. Articaine The risk or severity of methemoglobinemia can be increased when Inotuzumab ozogamicin is combined with Articaine. Asciminib The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Asciminib. Asfotase alfa The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Asfotase alfa. Asunaprevir The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Asunaprevir. Atezolizumab The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Atezolizumab. Atoltivimab The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Atoltivimab. Avanafil The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Avanafil. Avatrombopag The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Avatrombopag. Avelumab The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Avelumab. Axitinib The serum concentration of Axitinib can be increased when it is combined with Inotuzumab ozogamicin. Bamlanivimab The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Bamlanivimab. Basiliximab The risk or severity of adverse effects can be increased when Basiliximab is combined with Inotuzumab ozogamicin. Bebtelovimab The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Bebtelovimab. Belantamab mafodotin The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Belantamab mafodotin. Belimumab The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Belimumab. Belinostat The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Belinostat. Belumosudil The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Belumosudil. Bendamustine The serum concentration of Bendamustine can be increased when it is combined with Inotuzumab ozogamicin. Benralizumab The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Benralizumab. Benzocaine The risk or severity of methemoglobinemia can be increased when Inotuzumab ozogamicin is combined with Benzocaine. Benzyl alcohol The risk or severity of methemoglobinemia can be increased when Inotuzumab ozogamicin is combined with Benzyl alcohol. Berotralstat The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Berotralstat. Besilesomab The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Besilesomab. Betrixaban The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Betrixaban. Bevacizumab The risk or severity of adverse effects can be increased when Bevacizumab is combined with Inotuzumab ozogamicin. Bezlotoxumab The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Bezlotoxumab. Bimekizumab The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Bimekizumab. Binimetinib The serum concentration of Binimetinib can be increased when it is combined with Inotuzumab ozogamicin. Bisoprolol The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Bisoprolol. Blinatumomab The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Blinatumomab. Bortezomib The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Bortezomib. Bosutinib The serum concentration of Bosutinib can be increased when it is combined with Inotuzumab ozogamicin. Brentuximab The serum concentration of Brentuximab vedotin can be increased when it is combined with Inotuzumab ozogamicin. Brodalumab The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Brodalumab. Brolucizumab The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Brolucizumab. Bupivacaine The risk or severity of methemoglobinemia can be increased when Inotuzumab ozogamicin is combined with Bupivacaine. Burosumab The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Burosumab. Butacaine The risk or severity of methemoglobinemia can be increased when Inotuzumab ozogamicin is combined with Butacaine. Butamben The risk or severity of methemoglobinemia can be increased when Inotuzumab ozogamicin is combined with Butamben. Cabazitaxel The serum concentration of Cabazitaxel can be increased when it is combined with Inotuzumab ozogamicin. Cabergoline The serum concentration of Cabergoline can be increased when it is combined with Inotuzumab ozogamicin. Canagliflozin The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Canagliflozin. Canakinumab The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Canakinumab. Caplacizumab The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Caplacizumab. Capmatinib The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Capmatinib. Capromab pendetide The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Inotuzumab ozogamicin. Capsaicin The risk or severity of methemoglobinemia can be increased when Inotuzumab ozogamicin is combined with Capsaicin. Carfilzomib The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Carfilzomib. Carvedilol The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Carvedilol. Casirivimab The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Casirivimab. Catumaxomab The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Catumaxomab. Cemiplimab The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Cemiplimab. Ceritinib The serum concentration of Ceritinib can be increased when it is combined with Inotuzumab ozogamicin. Certolizumab pegol The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Certolizumab pegol. Cetuximab The risk or severity of adverse effects can be increased when Cetuximab is combined with Inotuzumab ozogamicin. Chloroprocaine The risk or severity of methemoglobinemia can be increased when Inotuzumab ozogamicin is combined with Chloroprocaine. Cilgavimab The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Cilgavimab. Cinchocaine The risk or severity of methemoglobinemia can be increased when Inotuzumab ozogamicin is combined with Cinchocaine. Clarithromycin The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Clarithromycin. Clobazam The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Clobazam. Clofazimine The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Clofazimine. Clomifene The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Clomifene. Cobicistat The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Cobicistat. Cobimetinib The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Cobimetinib. Cocaine The risk or severity of methemoglobinemia can be increased when Inotuzumab ozogamicin is combined with Cocaine. Colchicine The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Colchicine. Conivaptan The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Conivaptan. Conjugated estrogens Conjugated estrogens may increase the thrombogenic activities of Inotuzumab ozogamicin. Copanlisib The serum concentration of Copanlisib can be increased when it is combined with Inotuzumab ozogamicin. Crizotinib The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Crizotinib. Curcumin The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Curcumin. Cyclosporine The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Cyclosporine. Dabigatran etexilate The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Dabigatran etexilate. Dabrafenib The serum concentration of Dabrafenib can be increased when it is combined with Inotuzumab ozogamicin. Daclatasvir The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Daclatasvir. Dacomitinib The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Dacomitinib. Dactinomycin The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Dactinomycin. Daptomycin The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Daptomycin. Daratumumab The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Daratumumab. Darbepoetin alfa The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Inotuzumab ozogamicin. Darolutamide The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Darolutamide. You Might Also Read Flurazepam; Indications/Uses, Dosage, Side Effects, Interactions, Pregnancy Elotuzumab The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Elotuzumab. Emapalumab The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Emapalumab. Emicizumab The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Emicizumab. Enasidenib The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Enasidenib. Enfortumab vedotin The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Enfortumab vedotin. Entrectinib The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Entrectinib. Eptinezumab The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Eptinezumab. Erdafitinib The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Erdafitinib. Erenumab The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Erenumab. Ertugliflozin The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Ertugliflozin. Erythromycin The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Erythromycin. Erythropoietin The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Inotuzumab ozogamicin. Esterified estrogens Esterified estrogens may increase the thrombogenic activities of Inotuzumab ozogamicin. Estetrol Estetrol may increase the thrombogenic activities of Inotuzumab ozogamicin. Estradiol Estradiol may increase the thrombogenic activities of Inotuzumab ozogamicin. Estradiol acetate Estradiol acetate may increase the thrombogenic activities of Inotuzumab ozogamicin. Estradiol benzoate Estradiol benzoate may increase the thrombogenic activities of Inotuzumab ozogamicin. Estradiol cypionate Estradiol cypionate may increase the thrombogenic activities of Inotuzumab ozogamicin. Estradiol valerate Estradiol valerate may increase the thrombogenic activities of Inotuzumab ozogamicin. Estriol Estriol may increase the thrombogenic activities of Inotuzumab ozogamicin. Estrone Estrone may increase the thrombogenic activities of Inotuzumab ozogamicin. Estrone sulfate Estrone sulfate may increase the thrombogenic activities of Inotuzumab ozogamicin. Ethinylestradiol Ethinylestradiol may increase the thrombogenic activities of Inotuzumab ozogamicin. Ethyl chloride The risk or severity of methemoglobinemia can be increased when Inotuzumab ozogamicin is combined with Ethyl chloride. Etidocaine The risk or severity of methemoglobinemia can be increased when Inotuzumab ozogamicin is combined with Etidocaine. Etoposide The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Etoposide. Everolimus The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Everolimus. Evolocumab The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Evolocumab. Fanolesomab The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Fanolesomab. Favipiravir The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Favipiravir. Fedratinib The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Fedratinib. Fexofenadine The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Fexofenadine. Filgotinib The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Filgotinib. Flibanserin The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Flibanserin. Fluconazole The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Fluconazole. Fostemsavir The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Fostemsavir. Fremanezumab The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Fremanezumab. Futibatinib The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Futibatinib. Galcanezumab The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Galcanezumab. Gemcitabine The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Gemcitabine. Gemtuzumab ozogamicin The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Inotuzumab ozogamicin. Gilteritinib The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Gilteritinib. Glasdegib The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Glasdegib. Glecaprevir The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Glecaprevir. Golimumab The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Golimumab. Grazoprevir The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Grazoprevir. Guselkumab The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Guselkumab. Hepatitis B The risk or severity of adverse effects can be increased when Hepatitis B immune globulin is combined with Inotuzumab ozogamicin. cytomegalovirus The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Human cytomegalovirus immune globulin. Human immunoglobulin G The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Inotuzumab ozogamicin. immune globulin The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Human Rho(D) immune globulin. Human varicella-zoster The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Human varicella-zoster immune globulin. Ibalizumab The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Ibalizumab. Ibritumomab tiuxetan The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Inotuzumab ozogamicin. Idarucizumab The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Idarucizumab. Idelalisib The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Idelalisib. Imdevimab The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Imdevimab. Imipramine The serum concentration of Imipramine can be increased when it is combined with Inotuzumab ozogamicin. Imlifidase The therapeutic efficacy of Inotuzumab ozogamicin can be decreased when used in combination with Imlifidase. Indacaterol The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Indacaterol. Inebilizumab The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Inebilizumab. Infliximab The risk or severity of adverse effects can be increased when Infliximab is combined with Inotuzumab ozogamicin. Ipilimumab The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Ipilimumab. Isatuximab The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Isatuximab. Isavuconazole The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Isavuconazole. Isavuconazonium The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Isavuconazonium. Istradefylline The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Istradefylline. Itraconazole The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Itraconazole. You Might Also Read Tretinoinum - Indications, Contraindications Ketoconazole The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Ketoconazole. Lanadelumab The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Lanadelumab. Lapatinib The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Lapatinib. Larotrectinib The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Larotrectinib. Lasmiditan The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Lasmiditan. Ledipasvir The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Ledipasvir. Lefamulin The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Lefamulin. Lemborexant The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Lemborexant. Lenvatinib The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Lenvatinib. Levobupivacaine The risk or severity of methemoglobinemia can be increased when Inotuzumab ozogamicin is combined with Levobupivacaine. Levoketoconazole The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Levoketoconazole. Levothyroxine The serum concentration of Inotuzumab ozogamicin can be decreased when it is combined with Levothyroxine. Lidocaine The risk or severity of methemoglobinemia can be increased when Inotuzumab ozogamicin is combined with Lidocaine. Linagliptin The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Linagliptin. Lomitapide The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Lomitapide. Lonafarnib The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Lonafarnib. Loncastuximab The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Loncastuximab tesirine. Loperamide The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Loperamide. Lopinavir The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Lopinavir. Lorlatinib The serum concentration of Inotuzumab ozogamicin can be decreased when it is combined with Lorlatinib. Loxapine The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Loxapine. Lumacaftor The serum concentration of Inotuzumab ozogamicin can be decreased when it is combined with Lumacaftor. Lusutrombopag The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Lusutrombopag. Maftivimab The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Maftivimab. Mannitol The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Mannitol. Margetuximab The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Margetuximab. Maribavir The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Maribavir. Mefloquine The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Mefloquine. Meloxicam The risk or severity of methemoglobinemia can be increased when Inotuzumab ozogamicin is combined with Meloxicam. Mepivacaine The risk or severity of methemoglobinemia can be increased when Inotuzumab ozogamicin is combined with Mepivacaine. Mepolizumab The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Mepolizumab. Mestranol Mestranol may increase the thrombogenic activities of Inotuzumab ozogamicin. Methoxy polyethylene The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Inotuzumab ozogamicin. Methylene blue The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Methylene blue. Mifepristone The serum concentration of Inotuzumab ozogamicin can be decreased when it is combined with Mifepristone. Mirabegron The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Mirabegron. Mitapivat The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Mitapivat. Mogamulizumab The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Mogamulizumab. Morphine The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Morphine. Mosunetuzumab The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Mosunetuzumab. Muromonab The risk or severity of adverse effects can be increased when Muromonab is combined with Inotuzumab ozogamicin. Natalizumab The risk or severity of adverse effects can be increased when Natalizumab is combined with Inotuzumab ozogamicin. Necitumumab The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Necitumumab. Neratinib The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Neratinib. Netupitant The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Netupitant. Nilotinib The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Nilotinib. Nintedanib The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Nintedanib. Nivolumab The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Nivolumab. Norgestimate The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Norgestimate. Nortriptyline The serum concentration of Nortriptyline can be increased when it is combined with Inotuzumab ozogamicin. Obiltoxaximab The risk or severity of adverse effects can be increased when Obiltoxaximab is combined with Inotuzumab ozogamicin. Obinutuzumab The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Obinutuzumab. Ocrelizumab The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Ocrelizumab. Odesivimab The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Odesivimab. Ofatumumab The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Ofatumumab. Olaratumab The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Olaratumab. Omadacycline The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Omadacycline. Omalizumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Inotuzumab ozogamicin. Ombitasvir The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Ombitasvir. Osimertinib The serum concentration of Osimertinib can be increased when it is combined with Inotuzumab ozogamicin. Oxetacaine The risk or severity of methemoglobinemia can be increased when Inotuzumab ozogamicin is combined with Oxetacaine. Oxybuprocaine The risk or severity of methemoglobinemia can be increased when Inotuzumab ozogamicin is combined with Oxybuprocaine. Pacritinib The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Pacritinib. Palbociclib The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Palbociclib. Paliperidone The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Paliperidone. Palivizumab The risk or severity of adverse effects can be increased when Palivizumab is combined with Inotuzumab ozogamicin. Panitumumab The risk or severity of adverse effects can be increased when Panitumumab is combined with Inotuzumab ozogamicin. Panobinostat The serum concentration of Panobinostat can be increased when it is combined with Inotuzumab ozogamicin. Paritaprevir The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Paritaprevir. Pazopanib The serum concentration of Pazopanib can be increased when it is combined with Inotuzumab ozogamicin. Peginesatide The risk or severity of Thrombosis can be increased when Peginesatide is combined with Inotuzumab ozogamicin. Pembrolizumab The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Pembrolizumab. Pertuzumab The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Pertuzumab. Pexidartinib Inotuzumab ozogamicin may increase the hepatotoxic activities of Pexidartinib. Phenol The risk or severity of methemoglobinemia can be increased when Inotuzumab ozogamicin is combined with Phenol. Pibrentasvir The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Pibrentasvir. Pitolisant The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Pitolisant. Polatuzumab vedotin The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Polatuzumab vedotin. Polyestradiol phosphate Polyestradiol phosphate may increase the thrombogenic activities of Inotuzumab ozogamicin. Pomalidomide The serum concentration of Pomalidomide can be increased when it is combined with Inotuzumab ozogamicin. Ponatinib The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Ponatinib. Posaconazole The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Posaconazole. Pralsetinib The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Pralsetinib. Pramocaine The risk or severity of methemoglobinemia can be increased when Inotuzumab ozogamicin is combined with Pramocaine. Pravastatin The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Pravastatin. Prednisolone phosphate The serum concentration of Inotuzumab ozogamicin can be decreased when it is combined with Prednisolone phosphate. Prilocaine The risk or severity of methemoglobinemia can be increased when Inotuzumab ozogamicin is combined with Prilocaine. Procaine The risk or severity of methemoglobinemia can be increased when Inotuzumab ozogamicin is combined with Procaine. Propafenone The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Propafenone. Proparacaine The risk or severity of methemoglobinemia can be increased when Inotuzumab ozogamicin is combined with Proparacaine. Propoxycaine The risk or severity of methemoglobinemia can be increased when Inotuzumab ozogamicin is combined with Propoxycaine. Quinestrol Quinestrol may increase the thrombogenic activities of Inotuzumab ozogamicin. Quinidine The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Quinidine. Quinine The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Quinine. Ramucirumab The risk or severity of adverse effects can be increased when Ramucirumab is combined with Inotuzumab ozogamicin. Ranibizumab The risk or severity of adverse effects can be increased when Ranibizumab is combined with Inotuzumab ozogamicin. Ranolazine The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Ranolazine. Ravulizumab The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Ravulizumab. Raxibacumab The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Raxibacumab. Regorafenib The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Regorafenib. Relugolix The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Relugolix. Reserpine The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Reserpine. Reslizumab The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Reslizumab. Revefenacin The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Revefenacin. Rifampicin The serum concentration of Inotuzumab ozogamicin can be decreased when it is combined with Rifampicin. Rifamycin The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Rifamycin. Rimegepant The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Rimegepant. Riociguat The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Riociguat. Ripretinib The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Ripretinib. Risankizumab The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Risankizumab. Ritonavir The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Ritonavir. Rituximab The risk or severity of adverse effects can be increased when Rituximab is combined with Inotuzumab ozogamicin. Rivaroxaban The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Rivaroxaban. Rolapitant The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Rolapitant. Romidepsin The serum concentration of Romidepsin can be increased when it is combined with Inotuzumab ozogamicin. Romosozumab The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Romosozumab. Ropivacaine The risk or severity of methemoglobinemia can be increased when Inotuzumab ozogamicin is combined with Ropivacaine. Sacituzumab The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Sacituzumab govitecan. Sapropterin The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Sapropterin. Saquinavir The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Saquinavir. Sarecycline The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Sarecycline. Sarilumab The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Sarilumab. Secukinumab The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Secukinumab. Selexipag The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Selexipag. Selumetinib The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Selumetinib. Sildenafil The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Sildenafil. Silodosin The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Silodosin. Siltuximab The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Siltuximab. Simeprevir The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Simeprevir. Simvastatin The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Simvastatin. Sirolimus The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Sirolimus. Sitagliptin The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Sitagliptin. Sofosbuvir The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Sofosbuvir. Sorafenib The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Sorafenib. Sotagliflozin The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Sotagliflozin. Sotorasib The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Sotorasib. Sotrovimab The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Sotrovimab. Spesolimab The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Spesolimab. St. John’s Wort The serum concentration of Inotuzumab ozogamicin can be decreased when it is combined with St. John’s Wort. Stiripentol The excretion of Inotuzumab ozogamicin can be decreased when combined with Stiripentol. Sulesomab The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Sulesomab. Sutimlimab The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Sutimlimab. Suvorexant The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Suvorexant. Estrogens, A Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Inotuzumab ozogamicin. Estrogens, B Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Inotuzumab ozogamicin. Tacrolimus The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Tacrolimus. Tafasitamab The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Tafasitamab. Talazoparib The serum concentration of Talazoparib can be increased when it is combined with Inotuzumab ozogamicin. Tamoxifen The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Tamoxifen. Tazemetostat The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Tazemetostat. Technetium The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Technetium Tc-99m sestamibi. Tegaserod The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Tegaserod. Telaprevir The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Telaprevir. Temsirolimus The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Temsirolimus. Tenofovir disoproxil The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Tenofovir disoproxil. Tepotinib The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Tepotinib. Tetanus immune The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Tetanus immune globulin, human. Tetracaine The risk or severity of methemoglobinemia can be increased when Inotuzumab ozogamicin is combined with Tetracaine. Tezacaftor The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Tezacaftor. Tezepelumab The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Tezepelumab. Tibolone Tibolone may increase the thrombogenic activities of Inotuzumab ozogamicin. Ticagrelor The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Ticagrelor. Tildrakizumab The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Tildrakizumab. Tipranavir The serum concentration of Inotuzumab ozogamicin can be decreased when it is combined with Tipranavir. Tisotumab vedotin The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Tisotumab vedotin. Tivozanib The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Tivozanib. Tixagevimab The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Tixagevimab. Tocilizumab The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Tocilizumab. Tolvaptan The serum concentration of Tolvaptan can be increased when it is combined with Inotuzumab ozogamicin. Topotecan The serum concentration of Topotecan can be increased when it is combined with Inotuzumab ozogamicin. Toremifene The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Toremifene. Tositumomab The risk or severity of adverse effects can be increased when Tositumomab is combined with Inotuzumab ozogamicin. Tralokinumab The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Tralokinumab. Trastuzumab The risk or severity of adverse effects can be increased when Trastuzumab is combined with Inotuzumab ozogamicin. Trastuzumab The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Trastuzumab deruxtecan. Trastuzumab The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Trastuzumab emtansine. Trazodone The serum concentration of Inotuzumab ozogamicin can be decreased when it is combined with Trazodone. Tremelimumab The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Tremelimumab. Trilaciclib The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Trilaciclib. Trimipramine The serum concentration of Trimipramine can be increased when it is combined with Inotuzumab ozogamicin. Tucatinib Tucatinib may decrease the excretion rate of Inotuzumab ozogamicin which could result in a higher serum level. Ubrogepant The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Ubrogepant. Umbralisib The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Umbralisib. Umeclidinium The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Umeclidinium. Ustekinumab The risk or severity of adverse effects can be increased when Ustekinumab is combined with Inotuzumab ozogamicin. Valoctocogene roxaparvovec The therapeutic efficacy of Valoctocogene roxaparvovec can be decreased when used in combination with Inotuzumab ozogamicin. Vandetanib The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Vandetanib. Vardenafil The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Vardenafil. Vedolizumab The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Vedolizumab. Velpatasvir The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Velpatasvir. Vemurafenib The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Vemurafenib. Venetoclax The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Venetoclax. Verapamil The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Verapamil. Vinblastine The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Vinblastine. Vincristine The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Vincristine. Vinflunine The serum concentration of Vinflunine can be increased when it is combined with Inotuzumab ozogamicin. Voclosporin The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Voclosporin. Vorapaxar The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Vorapaxar. Voxilaprevir The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Voxilaprevir. You Might Also Read Dexlansoprazole, Uses, Dosage, Side Effects, InteractionsPregnancy and Lactation US FDA pregnancy category Not Assigned: Pregnancy Drugs that have caused, are suspected to have caused, or may be expected to cause, an increased incidence of human fetal malformations or irreversible damage. These drugs may also have adverse pharmacological effects. Accompanying texts should be consulted for further details. The US FDA has amended the pregnancy labeling rule for prescription drug products to require labeling that includes a summary of risk, a discussion of the data supporting that summary, and relevant information to help healthcare providers make prescribing decisions and counsel women about the use of drugs during pregnancy. Pregnancy categories A, B, C, D, and X are being phased out. Lactation The effects in the nursing infant are unknown. Women should not breastfeed during therapy and for at least 2 months after the last dose. How should this medicine be used? Inotuzumab ozogamicin injection comes as powder to be mixed with liquid to be injected intravenously (into a vein) by a doctor or nurse in a hospital or medical facility. It is usually injected on days 1, 8, and 15 of a 3- to 4-week cycle. The cycle may be repeated every 4 weeks as recommended by your doctor. The length of your treatment depends on how well your body responds to the medication and the side effects that you experience. Your doctor may need to interrupt or stop your treatment, lower your dose, or treat you with additional medications, depending on your response to inotuzumab ozogamicin and any side effects that you experience. You will receive certain medications to help prevent a reaction before you receive each dose of inotuzumab ozogamicin. Tell your doctor or nurse if you experience any of the following symptoms during and for at least one hour after the end of infusion: fever, chills, rash, shortness of breath, or difficulty breathing. Talk to your doctor about how you are feeling during and after your treatment. What special precautions should I follow? Before using inotuzumab ozogamicin injection, tell your doctor and pharmacist if you are allergic to inotuzumab ozogamicin, any other medications, or any of the ingredients in inotuzumab ozogamicin injection. Ask your pharmacist for a list of the ingredients. tell your doctor and pharmacist what other prescription and nonprescription medications, vitamins, nutritional supplements, and herbal products you are taking or plan to take. Be sure to mention any of the following: amiodarone (Pacerone, Nexterone); chloroquine (Aralen); clarithromycin (Biaxin, in Prevpac); disopyramide (Norpace); erythromycin (E.E.S., E-Mycin, P.C.E, others); haloperidol; methadone (Dolophine, Methadose); nefazodone; pimozide (Orap); procainamide; quinidine (in Nuedexta); sotalol (Betapace, Betapace AF, Sorine); and thioridazine. Your doctor may need to change the doses of your medications or monitor you carefully for side effects. Many other medications may also interact with inotuzumab ozogamicin, so be sure to tell your doctor about all the medications you are taking, even those that do not appear on this list. tell your doctor if you or anyone in your family has or has ever had a prolonged QT interval (a rare heart problem that may cause irregular heartbeat, fainting, or sudden death). Also, tell your doctor if you have or have ever had a low level of potassium or magnesium in your blood or kidney disease. tell your doctor if you are pregnant or plan to become pregnant. If you are a female, you should not become pregnant while you are receiving inotuzumab ozogamicin and for at least 8 months after your final dose. Talk to your doctor about birth control methods that will work for you. If you are a male, you and your female partner should use birth control during your treatment and continue to use birth control for at least 5 months after your final dose. If you or your partner become pregnant while receiving inotuzumab ozogamicin, call your doctor. Inotuzumab ozogamicin may harm the fetus. tell your doctor if you are breastfeeding. Your doctor may tell you not to breastfeed during your treatment with inotuzumab ozogamicin injection and for at least 2 months after your final dose. you should know that this medication may decrease fertility in men and women. Talk to your doctor about the risks of receiving inotuzumab ozogamicin. References https://pubchem.ncbi.nlm.nih.gov/substance/252166478 https://go.drugbank.com/drugs/DB05889 https://www.cancer.gov/about-cancer/treatment/drugs/inotuzumabozogamicin https://en.wikipedia.org/wiki/Inotuzumab_ozogamicin https://medlineplus.gov/druginfo/meds/a617041.html https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cc7014b1-c775-411d-b374-8113248b4077 https://www.drugs.com/pregnancy/inotuzumab-ozogamicin.html Show More